The most active researchers, institutions, and subtopics in Pancreatic Cancer, from recent PubMed records. Public authorship only, every figure verifiable by PMID.
Analyzed 600 recent PubMed papers (2021-2026) matching "pancreatic cancer treatment KRAS". Source: NLM PubMed. Generated July 2026.
| # | Researcher | Affiliation | Papers |
|---|---|---|---|
| 1 | Sajjakulnukit Peter | University of Michigan | 13 |
| 2 | Maitra Anirban | The University of Texas MD Anderson Cancer Center | 12 |
| 3 | Pasca di Magliano Marina | University of Michigan | 10 |
| 4 | Zhang Li | University of Michigan | 8 |
| 5 | Dusetti Nelson | Aix Marseille Univ | 8 |
| 6 | Park Wungki | Memorial Sloan Kettering Cancer Center | 7 |
| 7 | Iovanna Juan | Aix-Marseille Université and Institut Paoli-Calmettes | 7 |
| 8 | Wang Huamin | The University of Texas MD Anderson Cancer Center | 7 |
| 9 | Sugimoto Hikaru | University of Texas MD Anderson Cancer Center | 6 |
| 10 | Kalluri Raghu | University of Texas MD Anderson Cancer Center | 6 |
| 11 | Zheng Lei | The University of Texas at San Antonio | 6 |
| 12 | Singhal Rashi | University of Michigan | 6 |
| 13 | Reichert Maximilian | Technical University of Munich | 5 |
| 14 | Bekaii-Saab Tanios | Mayo Clinic | 5 |
| 15 | Zhao Dan | The University of Texas MD Anderson Cancer Center | 5 |
| 16 | Pant Shubham | The University of Texas MD Anderson Cancer Center | 5 |
| 17 | Ying Haoqiang | The University of Texas MD Anderson Cancer Center | 5 |
| 18 | Kurzrock Razelle | Medical College of Wisconsin and the LaBahn Pancreatic Can | 4 |
Ranked by recent publication volume; names not yet disambiguated and not citation-weighted. The full brief adds ORCID disambiguation, citation weighting, and clinical-trial investigator data.
Dual inhibition of tumor cells and tumor-associated neutrophils by anti-CXCR2 antibodies suppresses tumor growth and augments immu (2026) · PMID 42479087
Prognostic Relevance of Surgical Margins According to KRAS and BRAF Status in Colorectal Liver Metastases: BRAF-KRAS LiverMet Coll (2026) · PMID 42477180
LSD1-GLS2 axis drives subtype-specific chemoresistance in pancreatic cancer through glutaminolysis reprogramming. (2026) · PMID 42476970
Precision Medicine in Pancreatic Cancer: Targeting KRAS and Beyond. (2026) · PMID 42474629
CRISPR guided gene knockout in pancreatic ductal adenocarcinoma molecular mechanisms and therapeutic strategies. (2026) · PMID 42471534
A full Pancreatic Cancer brief adds citation weighting, name disambiguation, clinical-trial investigators, and a cited PDF, scoped to your exact molecule, competitor set, or region.